NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

Published on March 9, 2010 at 7:47 AM · No Comments

InterMune, Inc. (Nasdaq: ITMN) announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

Pirfenidone Regulatory Path – NDA and MAA

Continued on Next page >>

Sangart commences MP4CO Phase 1b study in sickle cell diseaseSangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines spec...
Furiex enters loan agreement with MidCap Financial, Silicon Valley BankFuriex Pharmaceuticals, Inc. announced today it has entered into a loan agreement with MidCap Financ...
Tacere announces reacquisition of HCV compound development, commercialization rights in AsiaTacere Therapeutics, an RNA interference (RNAi)-based therapeutics company, announced today that it ...
Clinical Data receives U.S. patent for vilazodoneClinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorph...
Eye-gaze technology opens world of communication for Rett Syndrome childrenSpecial eye-gaze technology now being used in the Department of Neurology at The Children's Hospital...
Allos Therapeutics' FOLOTYN data to be presented at 46th ASCO and 15th EHA CongressAllos Therapeutics, Inc. today announced that data on FOLOTYN® (pralatrexate injection) will be pres...
Report: 34 C>G of PPAR-γ gene might be a potential therapeutic target for colon cancerColorectal cancer is one of the major causes of cancer death in the developed countries. Accumulated...
Value-added insight and analysis of planning and deploying biomarkersReportlinker.com announces that a new market research report is available in its catalogue. Reportli...
Clinical studies reveal treatment with pirfenidone is safe and well-toleratedInterMune, Inc. (Nasdaq: ITMN) today announced that the results of a comprehensive review of safety ...
2 billion worldwide could het H1N1, says WHOThe WHO on Tuesday maintained that roughly two billion people could become infected with the H1N1 (s...
Federal Court rules FDA must reconsider Plan B decisionToday, the U.S. District Court for the Eastern District of New York rejected the Food and Drug Admin...
New type of yogurt fights bacteria that cause gastritis and stomach ulcersResults of the first human clinical studies confirm that a new yogurt fights the bacteria that cause...
Researchers link the extreme fatigue in pulmonary fibrosis to loss in body-rejuvenating R.E.M. sleepFamily, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md...
Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosisThe rights to key patents for an innovative screening tool for treatments for cystic fibrosis were t...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.